ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0070

Activation of Joint CD8+ TRM Localize Autoantibody Mediated Arthritis

Sahar Lotfi-Emran, Nicole Koziol and David Masopust, University of Minnesota, Minneapolis, MN

Meeting: ACR Convergence 2023

Keywords: Animal Model, Inflammation, T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In humans, upper respiratory infections have been associated with onset of Rheumatoid Arthritis. In mice, following viral infection, CD8+ T cells take up residence in joints and a portion become tissue resident memory cells (TRM). As these CD8+ TRM are not specific for a Rheumatoid Arthritis specific self-peptide, it is not clear if they contribute to disease activity. In the mouse uterus, re-activation of CD8+ TRM increases the permeability of the tissue to circulating antibodies. Utilizing the K/BxN serum transfer model, we demonstrate that local activation of CD8+ TRM generates persistent clinical arthritis at that site.

Methods: C57BL/6 mice received adoptive transfer of OT-1 transgenic CD8+ T cells, whose cognate antigen is SIINFEKL peptide. The next day, they are infected with vesicular stomatitis virus encoding SIINFEKL. Acute infection resolves over the course of a few weeks, virus is cleared, but tissues are persistently populated by OT-1 CD8+ TRM. These mice are OT-1mem mice. Naïve and OT-1mem mice receive dose limited volumes of arthritogenic serum from K/BxN mice. Two days later, they receive an injection of SIINFEKL peptide in their left ankle and left knee to reactivate OT-1 TRM. Ankles were scored for severity of clinical inflammation (0, no swelling/redness; 1, mild swelling/redness +/- swollen digits; 2, moderate swelling/redness; and 3, maximal swelling/redness with ankylosis) and their size was measured by calipers daily (from lateral to medial malleolus). After seven days, mice were sacrificed following intravascular stain injection, ankles fixed and decalcified for histology, and knees collected and processed to a single cell suspension for flow cytometry. (See Figure 1A for illustration of experimental groups.)

Results: Persistent clinical inflammation and increased size was found in the left ankle of OT-1mem mice that received K/BxN serum and injection of SIINFEKL, but not their right ankle, not in the left ankle of memory mice injected with an irrelevant peptide GP33, and not in the left ankle of memory mice that received SIINFEKL. (Figure 1B) By flow cytometry, the left, but not right, knee of memory mice that received K/BxN serum and injection of SIINFEKL contained significantly more OT-1 cells, endogenous CD8+ T cells, and B220+ B cells compared to Ot-1mem mice that received only K/BxN serum. This was not true of  the left knee of OT-1mem mice that received K/BxN serum and left knee injection with GP33, nor the left knee of OT-1mem mice that received only SIINFEKL injection. (Figure 2)

Conclusion: Persistent clinical inflammation is dependent on both K/BxN serum and local activation of virus specific joint CD8+ TRM and characterized by increased number of OT-1 transgenic CD8+ T cells, endogenous CD8+ T cells, and B220+ B cells. Thus, ‘bystander,’ virus specific, CD8+ TRM activation can localize systemic autoantibody mediated processes to the joint.

Supporting image 1

Figure 1. OT_1 CD8+ TRM activation in joints generates persistent clinical inflammation following K/BxN serum transfer arthritis. OT_1mem mice were generated by adoptive transfer of OT_1 cells followed by infection with VSV-OVA. OT_1 transgenic TCR recognizes the SIINFEKL peptide of ovalbumin and OT_1 cells rapidly expand and respond to VSV-OVA. 30+ days after infection, and well after clearance of virus, OT_1mem mice retain OT_1 TRM in tissues. OT_1mem and naive mice receive limited dose of K/BxN arthritogenic serum such that naive mice develop minimal disease. Two days after K/BxN serum, some mice receive SIINFEKL peptide or irrelevant peptide GP33 injections into left ankle and knee. Clinical disease activity is assessed daily by standardize scoring (0, no inflmmation, to 3, maximal swelling and ankylosis) and caliper measurements of ankles from malleolus to malleolus. A, Illustrated experimental groups. B, Left ankle score and change in ankle size. Two separate experiments. *p<0.05, **p<0.01ANOVA followed by Kruskal-Wallis comparison of each OT_1mem group to OT_1mem that received only K/BxN serum.

Supporting image 2

Figure 2. OT_1 CD8+ TRM activation locally increases CD8+ T cells and B cells at the the joint. Figure 1A illustrated experimental groups. Mouse knees were collected following intravascular staining, tissues were disaggregated in collagenase and DNAse solution, a single cell suspension was obtained, stained, and evaluated by flow cytometry with bead based counting to estimate total per tissue. Bead based counts for total CD8+ T cells, OT_1 CD8+ T cells, and non-OT_1 (endogenous) CD8+ T cells are shown in addition to CD4+ T cells, neutrophils (Ly6G+), and B cells (B220+). *p<0.05, **p<0.01ANOVA followed by Kruskal-Wallis comparison of each OT_1mem group to OT_1mem that received only K/BxN serum.


Disclosures: S. Lotfi-Emran: None; N. Koziol: None; D. Masopust: None.

To cite this abstract in AMA style:

Lotfi-Emran S, Koziol N, Masopust D. Activation of Joint CD8+ TRM Localize Autoantibody Mediated Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/activation-of-joint-cd8-trm-localize-autoantibody-mediated-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activation-of-joint-cd8-trm-localize-autoantibody-mediated-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology